Polyrizon Ltd - PLRZ Company Long-Term Liabilities

Polyrizon Ltd production facilities are currently engaged in clinical trials, while cleanrooms are being upgraded to meet global standards. Management is focused on expanding patents and achieving global certification for its antiviral sprays. Historical price action, where the indicator stands at 0.00, underscores the company's market strength driven by its unique physical nasal barrier technology, for which demand surges during epidemic periods.

PLRZ Polyrizon Limited: Company Long-Term Debts in the range 10/30/2024 - 10/28/2026

Analytical breakdowns for Polyrizon (PLRZ)

- price and consensus price forecast:
Market Price Polyrizon Limited|PLRZ - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Polyrizon|PLRZ - Enterprise Value
- book capitalization data:
Net Assets per Share Polyrizon|PLRZ - Book Capitalization|Market Capitalization to Book Value Ratio polyrizon-biotech.com|PLRZ - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Polyrizon Ltd|PLRZ - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Polyrizon Limited|PLRZ - Company Total Debt|Debts to Book Capitalization Ratio Polyrizon|PLRZ - Company Long-Term Debts|Short-Term Debt Polyrizon
Basic company analysis:PLRZ (Polyrizon Ltd)

Polyrizon Ltd (PLRZ) is effectively scaling the distribution of nasal barriers through pharmacy chains, which requires expenditures on sterile logistics. This metric accumulates all obligations with a maturity of more than one year, measuring long-term financial stability. Investors view this balance as either a tool for expansion or a default risk. The long-term debt dynamics of Polyrizon Ltd reflect a borrowing strategy aimed at infrastructure development. Analyzing this long-term debt allows for the determination of the business's margin of safety.

Direct competitors

Long-Term Debt vrtx.com VRTX|ALNY: Company Long-Term Debts|INSM - Company Long-Term Liabilities|United Therapeutics Corp. - Company Long-Term Debts|BioMarin Corp (BMRN) - Long-Term Debt Volume|BBIO (BridgeBio Pharma, Inc.) - Company Long-Term Debts|Company Long-Term Debts BGM|Company Long-Term Debt Cogent Biosciences, Inc. (COGT)|Company Long-Term Debt Xeris Biopharma Holdings, Inc. (XERS)|Company Long-Term Debts KROS|ARCT - Long-Term Debt Volume|Company Long-Term Liabilities Eton Pharmaceuticals|KMDA - Long-Term Liabilities|Company Long-Term Debts FULC|Abeona Therapeutics Inc. (ABEO) - Long-Term Debt|Company Long-Term Debts Mereo BioPharma Group (MREO)|Company Long-Term Indebtedness Protalix BioTherapeutics, Inc (PLX)|Pliant Therapeutics (PLRX) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings APLT (Applied Therapeutics Inc.)|Rein Therapeutics (RNTX) - Company Long-Term Debt|Long-Term Liabilities Gelteq Ltd GELS|Company Long-Term Debts Aytu Therapeutics (AYTU)|CMMB - Company Long-Term Loans and Borrowings|SRXH: Company Long-Term Debts|AEZS (Aeterna Zentaris Inc.) - Company Long-Term Debts|CYTH - Company Long-Term Debt|Company Long-Term Loans and Borrowings INZY|Company Long-Term Debt RPHM (Reneo Pharma)|Company Long-Term Liabilities COSCIENS Bio (CSCI)